Illumina (ILMN) Expected to Announce Earnings on Thursday

Illumina (NASDAQ:ILMN) is anticipated to issue its Q3 2025 results after the market closes on Thursday, October 30th. Analysts expect the company to announce earnings of $1.16 per share and revenue of $1.0655 billion for the quarter. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS.Parties may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Thursday, October 30, 2025 at 4:30 PM ET.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.17. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The firm had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter in the previous year, the firm posted $0.36 earnings per share. The company’s revenue was down 4.8% on a year-over-year basis. On average, analysts expect Illumina to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Illumina Stock Performance

Illumina stock opened at $97.23 on Thursday. The company has a 50 day moving average price of $98.17 and a 200-day moving average price of $91.11. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.41 and a current ratio of 1.81. Illumina has a fifty-two week low of $68.70 and a fifty-two week high of $156.66. The company has a market capitalization of $14.94 billion, a PE ratio of 12.31, a P/E/G ratio of 2.44 and a beta of 1.40.

Analyst Ratings Changes

ILMN has been the subject of several research analyst reports. Morgan Stanley lifted their price target on shares of Illumina from $100.00 to $105.00 and gave the company an “equal weight” rating in a research note on Monday, August 4th. Wall Street Zen downgraded shares of Illumina from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. Canaccord Genuity Group boosted their price objective on shares of Illumina from $99.00 to $105.00 and gave the stock a “hold” rating in a research note on Friday, August 1st. Weiss Ratings reissued a “sell (d+)” rating on shares of Illumina in a research note on Wednesday, October 8th. Finally, Robert W. Baird boosted their price objective on shares of Illumina from $84.00 to $105.00 and gave the stock a “neutral” rating in a research note on Monday, July 28th. Five analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Illumina presently has a consensus rating of “Hold” and a consensus price target of $115.25.

Hedge Funds Weigh In On Illumina

A number of large investors have recently made changes to their positions in ILMN. Duquesne Family Office LLC acquired a new position in shares of Illumina during the second quarter worth $28,682,000. Quantinno Capital Management LP increased its position in shares of Illumina by 2,418.4% during the second quarter. Quantinno Capital Management LP now owns 203,940 shares of the life sciences company’s stock worth $19,458,000 after purchasing an additional 195,842 shares in the last quarter. HRT Financial LP acquired a new position in shares of Illumina during the second quarter worth $15,606,000. Bamco Inc. NY increased its position in shares of Illumina by 77.9% during the second quarter. Bamco Inc. NY now owns 247,472 shares of the life sciences company’s stock worth $23,611,000 after purchasing an additional 108,339 shares in the last quarter. Finally, Vident Advisory LLC increased its position in shares of Illumina by 46.6% during the second quarter. Vident Advisory LLC now owns 178,250 shares of the life sciences company’s stock worth $17,007,000 after purchasing an additional 56,641 shares in the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.